Alligator Bioscience: Can Alligator bite back? - Redeye

Redeye reevaluates Alligator Bioscience ahead of its first efficacy readout from mitazalimab later this year. Success with this can reverse the share’s turbulent ride since the return of mitazalimab from Janssen in 2019. In addition, Alligator’s other projects are advancing and nearing inflexion points, offering diversification options.

Länk till analysen i sin helhet: https://www.redeye.se/research/840448/alligator-bioscience-can-alligator-bite-back?utm_source=finwire&utm_medium=RSS